Table 2

Relation between uremic pruritus severity and the clinical and laboratory data

Mild
n=75
Moderate/severe
n=76
P value
Age (y), mean±SD51.9±15.653.0±12.70.54
Male/female, n42/3349/270.29
HD duration (y), median (IQR)3.0 (1.0–5.0)4.0 (2.0–10.0)0.002
History/comorbidities, n (%)
 History of allergy5 (6.7)12 (15.8)0.08
 Hypertension61 (81.3)55 (72.4)0.19
 Diabetes mellitus14 (18.7)18 (23.7)0.45
 HCV28 (37.3)31 (40.8)0.66
Used medications, n (%)
 Calcimate65 (86.7)63 (82.9)0.52
 Cinacalcet5 (6.7)6 (7.9)0.77
 Vitamin D14 (18.7)5 (6.6)0.03
 Analgesics12 (16.0)5 (6.6)0.07
Antihypertensives
 Beta blockers42 (56.0)46 (60.5)0.57
 Calcium channel blockers41 (54.7)35 (46.1)0.25
 ACE inhibitors33 (44.0)32 (42.1)0.81
 Vasodilators30 (40.0)22 (29.0)0.15
 Clonidine5 (6.7)3 (4.0)0.46
Hemodialysis parameters, mean±SD
 Frequency (session/wk)2.9±0.52.9±0.30.95
 Duration of session (h)3.9±0.53.9±0.40.46
 Ultrafiltration volume (L)2.1±0.82.4±1.00.06
 Pump flow rate (mL/min)267.9±38.1262.1±36.50.33
 Kt/V1.3±0.141.31±0.150.88
 Dry weight (kg)66.5±5.566.9±6.20.7
 Intradialytic weight gain (kg)2.4±0.62.7±0.50.68
Laboratory findings, mean±SD/median (IQR)
 Hb (g/L)10.1±1.910.1±2.10.88
 Creatinine (mg/dL)8.7±3.48.6±2.80.87
 Urea (mg/dL)121.7±43.9103.4±49.60.17
 Albumin (g/dL)4.0±0.63.7±0.50.01
 Calcium (mg/dL)9.1±1.29.0±1.20.38
 Phosphorus (mg/dL)5.5±1.95.8±1.90.28
 PTH (pg/mL)645.9 (423.7–962.9)683.5 (446.0–1287.6)0.72
 AST (U/L)4.5±2.34.4±2.20.87
 ALT (U/L)20.7±17.920.1±12.60.83
 Uric acid (mg/dL)4.6±2.04.4±2.40.93
 Ferritin (ng/mL)455.0 (325.5–1109.3)526.0 (372.0–965.0)0.48
 hsCRP (mg/L)108.0±38.2121.6±29.50.02
  • ALT, alanine transferase; AST, aspartate transferase; HCV, hepatitis C virus; HD, hemodialysis; hsCRP, high-sensitivity C-reactive protein; PTH, parathyroid hormone.